Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Public ClinicalTrials.gov record NCT01701050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Study identification
- NCT ID
- NCT01701050
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Janssen Diagnostics, LLC
- Industry
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Interventions
- Blood collection Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2013
- Primary completion
- Nov 9, 2016
- Completion
- Nov 9, 2016
- Last update posted
- Mar 7, 2017
2013 – 2016
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Phoenix | Arizona | 85016 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33905 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Dana-Faber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Minnesota Oncology Hematology | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89074 | — |
| New York Oncology Hematology | New York | New York | 12206 | — |
| Waverly Hematology Oncology | Cary | North Carolina | 27518 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Northwest Cancer Specialists | Portland | Oregon | 97213 | — |
| Abramson Cancer Center, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Baylor | Dallas | Texas | 75246 | — |
| Texas Oncology | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01701050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2017 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01701050 live on ClinicalTrials.gov.